Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Myo-inositol rescued insulin resistance and dyslipidemia in db/db mice

L. Long, Q. Huang, T. Song, Z. Dai

. 2024 ; 22 (2) : 74-80. [pub] 20240614

Language English Country Czech Republic

Document type Journal Article

Grant support
2022JJ70134 Hunan Provincial Natural Science Foundation of China - China
2022JJ80120 Hunan Provincial Natural Science Foundation of China - China

Myo-inositol (MI), present in a variety of foods, is essential in several important processes of cell physiology. In this study, we explored the protective effects of MI against hyperglycemia and dyslipidemia in db/db mice, a typical animal model of type 2 diabetes mellitus (T2DM). MI supplement effectively suppressed the high plasma glucose and insulin levels and markedly relieved the insulin resistance (IR) in the db/db mice, comparable to metformin's effects. In MIN6 pancreatic β cells, MI also restrained the upsurge of insulin secretion stimulated by high-concentration glucose but had no impact on the promoted cell proliferation. Moreover, MI abated the enhanced plasma triglyceride and total cholesterol levels in the db/db mice. Notably, the lipid droplet formation of mesenchymal stem cells (MSCs) from db/db mice was significantly diminished after the treatment of MI, indicating that MI could effectively inhibit the differentiation of db/db mouse MSCs into adipocytes. However, MI regretfully failed to control obesity in db/db mice. This work proved that MI significantly helped db/db mice's metabolic disorders, indicating that MI has potential as an effective adjunctive treatment for hyperglycemia and dyslipidemia in T2DM patients.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24011947
003      
CZ-PrNML
005      
20250507141029.0
007      
ta
008      
240711s2024 xr ad f 000 0|eng||
009      
AR
024    7_
$a 10.32725/jab.2024.009 $2 doi
035    __
$a (PubMed)38912862
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Long, Lingzhi $u Hunan Provincial People's Hospital (The First-affiliated Hospital of Hunan Normal University), Department of Pharmacy, Changsha, China
245    10
$a Myo-inositol rescued insulin resistance and dyslipidemia in db/db mice / $c L. Long, Q. Huang, T. Song, Z. Dai
520    9_
$a Myo-inositol (MI), present in a variety of foods, is essential in several important processes of cell physiology. In this study, we explored the protective effects of MI against hyperglycemia and dyslipidemia in db/db mice, a typical animal model of type 2 diabetes mellitus (T2DM). MI supplement effectively suppressed the high plasma glucose and insulin levels and markedly relieved the insulin resistance (IR) in the db/db mice, comparable to metformin's effects. In MIN6 pancreatic β cells, MI also restrained the upsurge of insulin secretion stimulated by high-concentration glucose but had no impact on the promoted cell proliferation. Moreover, MI abated the enhanced plasma triglyceride and total cholesterol levels in the db/db mice. Notably, the lipid droplet formation of mesenchymal stem cells (MSCs) from db/db mice was significantly diminished after the treatment of MI, indicating that MI could effectively inhibit the differentiation of db/db mouse MSCs into adipocytes. However, MI regretfully failed to control obesity in db/db mice. This work proved that MI significantly helped db/db mice's metabolic disorders, indicating that MI has potential as an effective adjunctive treatment for hyperglycemia and dyslipidemia in T2DM patients.
650    _2
$a zvířata $7 D000818
650    12
$a inzulinová rezistence $7 D007333
650    12
$a dyslipidemie $x farmakoterapie $x metabolismus $7 D050171
650    12
$a inositol $x farmakologie $x terapeutické užití $7 D007294
650    _2
$a myši $7 D051379
650    12
$a diabetes mellitus 2. typu $x farmakoterapie $x metabolismus $7 D003924
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a inzulin $x metabolismus $x krev $7 D007328
650    _2
$a mezenchymální kmenové buňky $x metabolismus $x účinky léků $7 D059630
650    _2
$a krevní glukóza $x metabolismus $x účinky léků $7 D001786
650    _2
$a beta-buňky $x účinky léků $x metabolismus $7 D050417
650    _2
$a tukové buňky $x metabolismus $x účinky léků $7 D017667
650    _2
$a hyperglykemie $x farmakoterapie $x metabolismus $7 D006943
655    _2
$a časopisecké články $7 D016428
700    1_
$a Huang, Qi $u Hunan Provincial People's Hospital (The First-affiliated Hospital of Hunan Normal University), Department of Pharmacy, Changsha, China
700    1_
$a Song, Tao $u Central South University, Xiangya Hospital, Department of Neurosurgery, Changsha, China
700    1_
$a Dai, Zhijie $u The Second Xiangya Hospital of Central South University, Department of Metabolism and Endocrinology, National Clinical Research Center for Metabolic Diseases, Changsha, China
773    0_
$w MED00012667 $t Journal of applied biomedicine $x 1214-0287 $g Roč. 22, č. 2 (2024), s. 74-80
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38912862 $y Pubmed
910    __
$a ABA008 $b B 2301 $c 1249 $y p $z 0
990    __
$a 20240711 $b ABA008
991    __
$a 20250507141026 $b ABA008
999    __
$a ok $b bmc $g 2316457 $s 1223799
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 22 $c 2 $d 74-80 $e 20240614 $i 1214-0287 $m Journal of applied biomedicine $n J Appl Biomed $x MED00012667
GRA    __
$a 2022JJ70134 $p Hunan Provincial Natural Science Foundation of China $2 China
GRA    __
$a 2022JJ80120 $p Hunan Provincial Natural Science Foundation of China $2 China
LZP    __
$b NLK124 $a Pubmed-20240711

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...